Consonance Capital Management LP Uni Qure N.V. Transaction History

Consonance Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $1.8 Million - $2.38 Million	-50,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $44.3 Million - $66.6 Million	-982,636 Reduced 95.16%	50,000 $2.25 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $4.15 Million - $7.66 Million	103,600 Added 11.15%	1,032,636 $49 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $18.5 Million - $37.2 Million	-499,166 Reduced 34.95%	929,036 $66.6 Million
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $19 Million - $37.1 Million	-483,327 Reduced 25.28%	1,428,202 $56.2 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $3.9 Million - $6.08 Million	-73,931 Reduced 3.72%	1,911,529 $149 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $2.44 Million - $6.1 Million	89,234 Added 4.71%	1,985,460 $118 Million
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $19.4 Million - $28.9 Million	851,161 Added 81.45%	1,896,226 $54.6 Million
Q1 2018 May 15, 2018	BUY	$17.1 - $26.61 $17.9 Million - $27.8 Million	1,045,065 New	1,045,065 $24.6 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.